COMMUNIQUÉS West-GlobeNewswire

Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
04/03/2019
- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH - - Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH - - Currently no available [...]
Orion Corporation: Managers' transactions - Virve Laitinen
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Virve Laitinen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Jari Karlson
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Jari Karlson Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Olli Huotari
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Olli Huotari Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Christer Nordstedt
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Christer Nordstedt Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]
Orion Corporation: Managers' transactions - Liisa Hurme
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Markku Huhta-Koivisto
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Markku Huhta-Koivisto Orion Corporation has received the following disclosure under Market Abuse Regulation [...]
Orion Corporation: Managers' transactions - Satu Ahomäki
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers' transactions - Timo Lappalainen
04/03/2019
ORION CORPORATION MANAGERS' TRANSACTIONS 4 March 2019 at 11.45 EET Orion Corporation: Managers' transactions - Timo Lappalainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]
Orion Group Financial Statement documents 2018 and Corporate Governance Statement published
04/03/2019
ORION CORPORATION STOCK EXCHANGE RELEASE 4 MARCH 2019 at 12.00 EET Orion Group Financial Statement documents 2018 and Corporate Governance Statement published Orion Group's Financial Statement documents for 2018 have [...]
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2018 Financial Results
04/03/2019
Conference Call Scheduled for March 7, 2019 at 11:00 am EASTERN DUBLIN, Ireland, March 04, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the [...]
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
04/03/2019
Orphazyme A/S Company announcement No. 05/2019 Company Registration No. 32266355 Copenhagen, Denmark, March 1, 2019 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), [...]
Tecan schedules Analyst and Media Conference on March 11 to discuss Full-Year 2018 Financial Results
04/03/2019
Männedorf, Switzerland, March 4, 2019 – The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media Conference to discuss the full-year 2018 financial results on Monday, March 11, 2019 at 09:00 am CET in [...]
Oasmia has completed a directed share issue of approximately 165 MSEK
04/03/2019
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) hereby announces that the Company has carried out a placing of shares in the Company, through a directed issue of 22,948,535 shares, corresponding to [...]
Nexstim Plc Publishes 2018 Annual Report
04/03/2019
Company announcement, Helsinki, 04.03.2019 at 09.15 Finnish time (EET) Nexstim Plc Publishes 2018 Annual Report Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), the targeted neuromodulation company [...]
NEXSTIM PLC FINANCIAL STATEMENTS RELEASE 2018
04/03/2019
Company announcement, Helsinki, 4 March 2019 at 9:00 am NEXSTIM PLC FINANCIAL STATEMENTS RELEASE 2018 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and [...]
Ossur Hf : Candidates to the Board of Directors
04/03/2019
Announcement no. 14/2019 4 March 2019 Candidates to the Board of Directors Enclosed are details on the candidates to the Board of Directors of Össur hf., to be elected at the Annual General Meeting held on Thursday, 7 [...]
Nightstar Therapeutics plc reaches agreement to be acquired by Biogen
04/03/2019
Biogen to acquire Nightstar for US$ 25.50 per share in cash Transaction expected to be completed by mid-year 2019 WALTHAM, Mass. and LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (" Nightstar [...]
Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology
04/03/2019
Biogen to acquire Nightstar Therapeutics for $25.50 per share Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering from rare inherited retinal diseases that [...]

Pages